We present 3 patients diagnosed with rhabdomyolysis 1–6 months after the initiation of
concomitant rosuvastatin and ticagrelor medication. A literature review and Food and Drug …

The high prevalence of statin and clarithromycin utilization creates potential for overlapping
use. The objectives of this MiniReview were to investigate the evidence base for drug‐drug …

Ever since evidence about the increased risk of stent thrombosis with drug eluting stents
(DES) surfaced in 2005, the Food and Drug Administration (FDA) has recommended the use …

Purpose The study aims to evaluate relationship between polymorphisms associated with a
reduced function of two transporter proteins resulting in increased exposure to rosuvastatin …

Ticagrelor and rosuvastatin are often used concomitantly after atherothrombotic events.
Several cases of rhabdomyolysis during concomitant ticagrelor and rosuvastatin have been …

Variability in the response to drug therapy is a widespread issue. It may be affected by
various factors, including, but not limited to age, sex, renal and hepatic function, as well as …

Backgrounds: A major side effect of statin, a widely used drug to treat hyperlipidemia, is
skeletal myopathy through cell apoptosis. The aim of this study is to investigate the roles of …

Background: Ticagrelor is a commonly used antiplatelet agent, but due to the stringent
criteria for trial population inclusion and the limited sample size, its safety profile has not …

An increased risk of new-onset diabetes mellitus has been recently reported for statin
therapy, and experimental studies have shown reduced glucose-stimulated insulin secretion …

Objective Drug interactions are a common cause of morbidity and mortality and may require
prompt discontinuation of therapeutic regimens due to harmful side effects. Patients with …